Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END USER COVERAGE GRID
2.1 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTERS FIVE FORCES
5 EPIDERMIOLOGY
6 PIPELINE ANALYSIS FOR ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET
7 SUMMARY WRITE UP (ECUADOR)
7.1 OVERVIEW
8 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: REGULATIONS
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 RISE IN GERIATRIC POPULATION
9.1.2 RISING INVESTMENT IN RESEARCH AND DEVELOPMENT
9.1.3 RISING CLINIAL TRIALS AND PRODUCT APPROVAL
9.1.4 RISING BURDEN OF ACUTE MYELOID LEUKEMIA
9.2 RESTRAINTS
9.2.1 ADVERSE EFFECTS ASSOCIATED WITH CANCER DRUGS
9.2.2 HIGH COST OF CANCER MEDICINE
9.3 OPPORTUNITIES
9.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS
9.3.2 RISE IN HEALTHCARE EXPENDITURE
9.3.3 RISE OF INNOVATIVE THERAPIES
9.4 CHALLENGES
9.4.1 LACK OF SKILLED PROFESSIONALS
9.4.2 STRINGENT REGULATIONS
10 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY COUNTRY
10.1.1 PERU
10.1.2 ECUADOR
11 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY SUB-TYPE
11.1 OVERVIEW
11.2 M3 (ACUTE PROMYELOCYTIC LEUKEMIA (APL))
11.3 M2 (ACUTE MYELOBLASTIC LEUKEMIA WITH MATURATION)
11.4 M4 (ACUTE MYELOMONOCYTIC LEUKEMIA)
11.5 M0 (UNDIFFERENTIATED ACUTE MYELOBASTIC LEUKEMIA)
11.6 M1 (ACUTE MYELOBLASTIC LEUKEMIA WITH MINIMAL MATURATION)
11.7 M5 (ACUTE MONOCYTIC LEUKEMIA)
11.8 M7 (ACUTE MEGAKARYOBLASTIC LEUKEMIA)
11.9 M6 (ACUTE ERYTHROID LEUKEMIA)
12 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS
12.1 OVERVIEW
12.2 CHEMOTHERAPY
12.2.1 CYTOSAR
12.2.2 DAUNORUBICIN
12.2.3 DOXORUBICIN
12.2.4 METHOTREXATE
12.2.5 DECITABINE
12.2.6 CLADRIBINE
12.2.7 OTHERS
12.3 TARGETED THERAPY
12.3.1 VENETOCLAX (VENCLEXTA)
12.3.2 MIDOSTAURIN (RYDAPT)
12.3.3 ENASIDENIB (IDHIFA)
12.3.4 OTHERS
12.4 IMMUNOTHERAPY
12.4.1 OBINUTUZUMAB (GAZYVA/GAZYVARO)
12.4.2 RITUXIMAB
12.4.3 INTERFERONS
12.4.4 ALEMTUZUMAB (CAMPATH)
12.4.5 OTHERS
13 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE
13.1 OVERVIEW
13.2 BRANDED
13.2.1 CYTOSAR
13.2.2 VENCLEXTA
13.2.3 RYDAPT
13.2.4 IDHIFA
13.2.5 GAZYVA/GAZYVARO
13.2.6 CAMPATH
13.2.7 OTHERS
13.3 GENERICS
14 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 PARENTERAL
14.2.1 INTRAVENOUS
14.2.2 SUBCUTANEOUS
14.2.3 OTHERS
14.3 ORAL
14.3.1 TABLET
14.3.2 CAPSULE
14.3.3 OTHERS
14.4 OTHERS
15 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE
15.1 OVERVIEW
15.2 GERIATRIC
15.3 ADULTS
15.3.1 MALE
15.3.2 FEMALE
15.4 PEDIATRIC
16 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.3 SPECIALTY CLINICS
16.4 AMBULATORY CENTERS
16.5 OTHERS
17 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 DIRECT TENDER
17.3 HOSPITAL PHARMACY
17.4 RETAIL PHARMACY
17.5 ONLINE PHARMACY
17.6 OTHERS
18 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: ECUADOR
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 PFIZER INC.( (2021)
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 PRODUCT PORTFOLIO
20.1.4 RECENT DEVELOPMENT
20.2 BRISTOL-MYERS SQUIBB COMPANY (2021)
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 PRODUCT PORTFOLIO
20.2.4 RECENT DEVELOPMENT
20.3 ABBVIE INC. (2021)
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 PRODUCT PORTFOLIO
20.3.4 RECENT DEVELOPMENTS
20.4 NOVARTIS AG (2021)
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 PRODUCT PORTFOLIO
20.4.4 RECENT DEVELOPMENT
20.5 F.HOFFMAN-LA ROCHE
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 PRODUCT PORTFOLIO
20.5.4 RECENT DEVELOPMENT
20.6 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.) (2021)
20.6.1 COMPANY SNAPSHOT
20.6.2 REVENUE ANALYSIS
20.6.3 PRODUCT PORTFOLIO
20.6.4 RECENT DEVELOPMENT
20.7 FRESENIUS KABI AG 2021)
20.7.1 COMPANY SNAPSHOT
20.7.2 REVENUE ANALYSIS
20.7.3 PRODUCT PORTFOLIO
20.7.4 RECENT DEVELOPMENT
20.8 ASTRA ZENECA (2021)
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENT
20.9 BOHRINGER INGELHEIM INTERNATIONAL GMBH (2021)
20.9.1 COMPANY SNAPSHOT
20.9.2 1.9.2 REVENUE ANALYSIS
20.9.3 PRODUCT PORTFOLIO
20.9.4 RECENT DEVELOPMENT
20.1 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) (2021)
20.10.1 COMPANY SNAPSHOT
20.10.2 REVENUE ANALYSIS
20.10.3 PRODUCT PORTFOLIO
20.10.4 RECENT DEVELOPMENTS
20.11 SUN PHARMACEUTICAL INDUSTRIES LTD.
20.11.1 COMPANY SNAPSHOT
20.11.2 REVENUE ANALYSIS
20.11.3 PRODUCT PORTFOLIO
20.11.4 RECENT DEVELOPMENT
20.12 TEVA PHARMACEUTICAL INDUSTRIES LTD
20.12.1 COMPANY SNAPSHOT
20.12.2 REVENUE ANALYSIS
20.12.3 PRODUCT PORTFOLIO
20.12.4 PRODUCT PORTFOLIO
20.13 VIATRIS INC. (2021)
20.13.1 COMPANY SNAPSHOT
20.13.2 REVENUE ANALYSIS
20.13.3 PRODUCT PORTFOLIO
20.13.4 RECENT DEVELOPMENTS
21 QUESTIONNAIRE
22 RELATED REPORTS
List of Table
TABLE 1 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)
TABLE 2 PERU ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY SUB-TYPE, 2020-2029 (USD THOUSAND)
TABLE 3 PERU ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 4 PERU CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 5 PERU TARGETED THERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 6 PERU IMMUNOTHERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 7 PERU ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 8 PERU BRANDED IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 9 PERU ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 10 PERU PARENTERAL IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 11 PERU ORAL IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 12 PERU ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD THOUSAND)
TABLE 13 PERU ADULTS IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD THOUSAND)
TABLE 14 PERU ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 15 PERU ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 16 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY SUB-TYPE, 2020-2029 (USD THOUSAND)
TABLE 17 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 18 ECUADOR CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 19 ECUADOR TARGETED THERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 20 ECUADOR IMMUNOTHERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 21 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 22 ECUADOR BRANDED IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 23 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 24 ECUADOR PARENTERAL IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 25 ECUADOR ORAL IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 26 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD THOUSAND)
TABLE 27 ECUADOR ADULTS IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD THOUSAND)
TABLE 28 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 29 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 30 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY SUB-TYPE, 2020-2029 (USD THOUSAND)
TABLE 31 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 32 ECUADOR CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 33 ECUADOR TARGETED THERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 34 ECUADOR IMMUNOTHERAPY IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 35 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 36 ECUADOR BRANDED IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DRUGS, 2020-2029 (USD THOUSAND)
TABLE 37 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 38 ECUADOR PARENTERAL IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 39 ECUADOR ORAL IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 40 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD THOUSAND)
TABLE 41 ECUADOR ADULTS IN ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD THOUSAND)
TABLE 42 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 43 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
List of Figure
FIGURE 1 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: SEGMENTATION
FIGURE 2 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: DROC ANALYSIS
FIGURE 4 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: COUNTRY VS REGIONAL MARKET ANALYSIS
FIGURE 5 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: DBMR POSITION GRID
FIGURE 8 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: END USER COVERAGE GRID
FIGURE 9 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: SEGMENTATION
FIGURE 10 INCREASED PREVALENCE OF CANCER AND RISE IN ONGOING CLINICAL TRIALS ARE EXPECTED TO DRIVE ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET FROM 2022 TO 2029
FIGURE 11 SUB-TYPE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET FROM 2022 & 2029
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET
FIGURE 13 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY SUB-TYPE, 2021
FIGURE 14 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY SUB-TYPE, 2022-2029 (USD THOUSAND)
FIGURE 15 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY SUB-TYPE, CAGR (2022-2029)
FIGURE 16 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY SUB-TYPE, LIFELINE CURVE
FIGURE 17 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY DRUGS, 2021
FIGURE 18 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY DRUGS, 2022-2029 (USD THOUSAND)
FIGURE 19 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY DRUGS, CAGR (2022-2029)
FIGURE 20 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY DRUGS, LIFELINE CURVE
FIGURE 21 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY DRUG TYPE, 2021
FIGURE 22 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY DRUG TYPE, 2022-2029 (USD THOUSAND)
FIGURE 23 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY DRUG TYPE, CAGR (2022-2029)
FIGURE 24 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 25 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 26 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD THOUSAND)
FIGURE 27 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 28 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 29 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY POPULATION TYPE, 2021
FIGURE 30 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY POPULATION TYPE, 2022-2029 (USD THOUSAND)
FIGURE 31 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY POPULATION TYPE, CAGR (2022-2029)
FIGURE 32 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 33 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY END USER, 2021
FIGURE 34 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY END USER, 2022-2029 (USD THOUSAND)
FIGURE 35 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 36 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 37 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 38 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD THOUSAND)
FIGURE 39 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 40 ECUADOR ACUTE MYELOID LEUKEMIA DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 41 ECUADOR ACUTE MYELOID LEUKEMIA MARKET: COMPANY SHARE 2021 (%)
